Bharat Biotech’s Covaxin phase 3 data shows 77.8 pc efficacy against COVID-19, says Lancet
Hyderabad (Telangana) [India]: Hyderabad-based Bharat Biotech on Friday announced that the Lancet peer-review confirmed the efficacy analysis of Bharat Biotech’s Covaxin.As per phase-three clinical trials